Validating electronic source data clinical trials

Clinical data is one of the most valuable assets to a pharmaceutical company.

Data is central to the whole clinical development process.

The company has signed deals with 50 customers since launch and has agreements with two electronic data capture systems to integrate their data feeds – Medidata and Aris Cloud.

An important concern in moving to electronic source data is the validation of such data.The cost per patient of Phase 3 clinical studies of new pharmaceuticals exceeds ,000, on average, according to benchmarking report, published by business intelligence firm.Phase 2 trials are comparatively cheaper, with the average per-patient cost falling just over ,300 per patient.Cambridge, Massachusetts-based Clinical Research IO, which developed an electronic platform for researchers to quickly capture data during clinical trials, has raised

An important concern in moving to electronic source data is the validation of such data.

The cost per patient of Phase 3 clinical studies of new pharmaceuticals exceeds $26,000, on average, according to benchmarking report, published by business intelligence firm.

Phase 2 trials are comparatively cheaper, with the average per-patient cost falling just over $19,300 per patient.

Cambridge, Massachusetts-based Clinical Research IO, which developed an electronic platform for researchers to quickly capture data during clinical trials, has raised $1.6 million in seed funding in a round led by NXT Ventures and Rally Ventures.

||

An important concern in moving to electronic source data is the validation of such data.The cost per patient of Phase 3 clinical studies of new pharmaceuticals exceeds $26,000, on average, according to benchmarking report, published by business intelligence firm.Phase 2 trials are comparatively cheaper, with the average per-patient cost falling just over $19,300 per patient.Cambridge, Massachusetts-based Clinical Research IO, which developed an electronic platform for researchers to quickly capture data during clinical trials, has raised $1.6 million in seed funding in a round led by NXT Ventures and Rally Ventures.

.6 million in seed funding in a round led by NXT Ventures and Rally Ventures.

bathroom-blowjob

Previously, the company raised 0,000, and the latest funding brings the company’s total to .4 million.This review discusses these barriers and potential solutions that can assist the clinical trial industry in achieving more wide-spread EDC use and the resulting improvement in operating efficiencies.

pcisecurity.ru

91 Comments

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>